ʻO keʻano o ke kumuʻo Brucial BCR-Abl no CLML

ʻO ka myelogenoususeukemiamia nui ʻOi aku ma mua o 95% o nā mea maʻi CML e lawe i ka chromosome chromosome (ph) ma ko lākou mau koko koko. A ua hoʻokumuʻia ka focr fcr-abl fusion e kahi translocation ma waena o ka burgene (abelgen murine ((9q34) o Chromosome 22 (22Q11). Ua hoʻohuiʻiaʻo ia i kānaʻoihana Fusion e kēia Genene Kinain ka hopena o cml.

ʻO BCR-Abl Fusion Gent, he mea nui ia i ka hoʻomohalaʻana o CML, nā lawelawe e like me ka hōʻailona diagnostic o cml. Kōkua kona meaʻike i ka mea hoʻomanawanui'S pane i Tyrostine Kinane Kinanes

Kanaka BCR-AblFusion ge ge ge ge ge ge gutimai Macro & Micro-hōʻike hōʻike no ka nānāʻana i ka nānāʻana o ka bcr-abl i nā mea maʻi cml. Kōkua i nā maʻi CML a me nā alakaʻi alakaʻi i nā lāʻau lapaʻau e hoʻopili i nā hoʻolālā Trapeutic no ka mea hoʻomanawanui e pono ai.bcr-Abl Fusion Gene, naoemea nuiI ka hoʻomohalaʻana o CML,lawelawe e like me ka hōʻailona diagnosticofCml. ^. Kōkua konaʻikemolihiahonui'sPane i Tyrostine Kinain Kinan (TKIS)awānana aloo iā Leukemia Recurrence, eiapono loato PonoCmlka hoʻokele hoʻomanawanui.

Kanaka BCR-Abl Fusion General UT mai Macro & Micro-hōʻike hōʻike no ka nānāʻana i kaʻike o ka bcr-abl i nā mea maʻi cml, AʻoaʻoCmlNā Dnangsisaalakaʻinā lāʻau lapaʻau clinicaltoopimazeʻO nā hoʻolālā Therapeutic no ka hoʻokele olakino maikaʻi.

HopohopoDNā Kūlana:Huakaiʻikeno ka3Nā Kūlana Kūʻai maʻamau (P210, P190, P230)no kaka uhi ākea apale mai nā hihia i hala;

Kūlā kiʻekiʻe:Hōʻike ka mana o ka waime ka hoo 1000 kope / ml,a ka mana lyophilizedof 500 kope / ML;

KūponoACCURRER: I[Nā KiʻiHonoa me ka weheʻole e pale aku ai i nā mea hoʻopunipuni&Nā Negatives;

ʻO ka hana maʻalahi a me ka maikaʻi:Palapala-Toku hana,manuahi manuahiHōʻike Hoʻohālikelike.aʻikeI loko60 mau minukeno kanā hopena kūpono a hilinaʻi hoʻi;

Hou houNā koho:Wai wai a me ka lyophilized i nā koho o nā mea kūʻai aku;

Ka hoʻohālikelike ākea:Kūpono me nā'ōnaehana pcr o ka pcr no ka pae'āina ākea.